双靶向抑制GSK3B和HDACs可减少卵巢癌小鼠模型的肿瘤生长并提高生存率
该研究在体外和免疫 competent 同基因小鼠模型中评估了新开发的双重抑制剂APCS-540(靶向糖原合成酶激酶3β和组蛋白去乙酰化酶)的抗肿瘤效果。APCS-540在人和小鼠卵巢癌细胞中显示出显著抗肿瘤作用,对顺铂耐药细胞有细胞毒性,与铂类联用可逆转顺铂耐药,并显著减少癌细胞侵袭。在BR-Luc小鼠模型中,APCS-540组较对照组生存率显著提高66%。
要点
- APCS-540在体外对人和小鼠卵巢癌细胞显示显著抗肿瘤效果。
- APCS-540对顺铂耐药癌细胞有细胞毒性,与铂类联用可逆转顺铂耐药。
- APCS-540组小鼠较对照组生存率显著提高66%。
核心结论
- 通过APCS-540双重抑制GSK3B和HDACs在体外和体内均显示出强效抗肿瘤活性,提示APCS-540可能为卵巢癌(包括铂耐药疾病)提供新的治疗选择。
研究设计与样本
- 体外研究使用人卵巢癌细胞(KURAMOCHI、OVCA420、OVSAHO)和小鼠卵巢癌细胞(BR-Luc、ID8、MOSE-HRas-Myc),并使用顺铂敏感(A2780)和顺铂耐药(A2780cis)细胞系评估APCS-540对化疗耐药的影响。
- 体内研究使用免疫 competent 同基因小鼠模型BR-Luc测试APCS-540对卵巢癌进展和生存的影响。
主要发现
- APCS-540在体外对人和小鼠卵巢癌细胞均显示出显著抗肿瘤效果。
- APCS-540对顺铂耐药癌细胞表现出明显细胞毒性,与铂类联用时逆转顺铂耐药。
- APCS-540显著减少癌细胞侵袭。
- 接受APCS-540治疗的小鼠较对照组小鼠生存率显著提高66%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the anti-tumor effect of a newly-developed dual inhibitor (APCS-540) of glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs) in ovarian cancer cells. METHODS: The effects of APCS-540 on cancer cell proliferation, migration, invasion and cancer stemness were investigated in vitro in human (KURAMOCHI, OVCA420, OVSAHO) and mouse (BR-Luc, ID8, MOSE-HRas-Myc) ovarian cancer cells. Cisplatin-sensitive (A2780) and cisplatin-resistant (A2780cis) cell lines were used to evaluate APCS-540's effect on chemoresistance. The immunocompetent syngeneic mouse model BR-Luc was used to test the effect of APCS-540 on ovarian cancer progression and survival. RESULTS: APCS-540 showed significant anti-tumor effects in vitro in both human and mouse ovarian cancer cells. Importantly, APCS-540 demonstrated marked cytotoxicity against cisplatin-resistant cancer cells and reversed cisplatin-resistance when used in combination with platinum. APCS-540 significantly decreased cancer cell invasion. A significant 66% increase in survival was observed in mice treated with APCS-540 compared to control mice. CONCLUSION: Dual inhibition of GSK3B and HDACs via APCS-540 showed potent anti-tumor activity in vitro and in vivo, suggesting that APCS-540 may provide a novel treatment option for ovarian cancer, including the platinum-resistant disease.
引用
- Taylan E, Zayou F, Murali R, et al. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model. Gynecol Oncol. 2020. PMID: 32698955. doi:10.1016/j.ygyno.2020.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。